Pulmonary administration of pharmaceutically active substances

• US 5,006,343 A
• Filed: 12/29/1988
• Issued: 04/09/1991
• Est. Priority Date: 12/29/1988
• Status: Expired due to Term

• Current Assignee: Altana Pharma AG (Takeda Pharmaceutical Company Limited)
• Original Assignee: Bradley J. Benson, Jorae Wright
• Inventors: Benson, Bradley J., Wright, JoRae
• Primary Examiner(s): Cashion, Jr., Merrell C.
• Assistant Examiner(s): Prater, P. L.
• Application Number:
  US07/295,926
• Time in Patent Office: 831 Days
• Field of Search: 424/450, 252/181, 264/4.6
• US Class Current: 424/450
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/0082 Lung surfactant, artificial mucus
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

Pulmonary administration of a pharmaceutically active substance useful for local or systemic action which comprises, liposomes containing an effective amount of a pharmaceutically active substance, and an amount of alveolar surfactant protein effective to enhance transport of the liposomes across a pulmonary surface.

Claims

1. A composition for pulmonary administration of a pharmaceutically active substance, said composition comprising 60-90% by weight liposome forming compound, 5-20% by weight pharmacentically active substance, and 5-20% by weight surfactant protein, based on the total weight of liposome-forming substance, pharmacentically active substance and alveolar surfactant protein, wherein said composition comprises liposomes.

2. The composition of claim 1 wherein said alveolar surfactant protein comprises at least one alveolar surfactant protein selected from alveolar surfactant protein SP-A, alveolar surfactant protein SP-B, and alveolar surfactant protein SP-C.

3. The composition of claim 1 wherein said pharmaceutically active substance is water insoluble.

4. The composition of claim 1 wherein said pharmaceutically active substance is water soluble.

5. The composition of claim 3 wherein said pharmaceutically active substance is Vitamin E.

6. The composition of claim 1 wherein said liposome-forming compound comprises 1-90% by weight dipalmitoyl phosphatidyl choline, 1-90% by weight phosphatidyl choline, 1-30% by weight phosphatidyl glycerol, and 1-30% by weight cholesterol.

7. A method of administering a pharmaceutically active substance which comprises applying to pulmonary surfaces for transport across said surfaces a composition comprising:

(a) liposomes formed from at least one liposome-forming compound, said liposomes containing an effective amount of a pharmaceutically active substance; and

(b) alveolar surfactant protein in an amount effective to enhance transport of said liposomes across a pulmonary surface.

8. The method of claim 7 wherein said composition is applied to the pulmonary surfaces in the form of an aerosol spray.

9. A method of preparing a composition for delivering a pharmaceutically active substance comprising:

(a) forming liposomes containing at least one liposome-forming compound and an effective amount of a pharmaceutically active substance; and

(b) adding alveolar surfactant protein in an amount effective to enhance transport of said liposomes across a pulmonary surface.